Today we announced that Arcus obtained a term loan facility from Hercules Capital, adding operational flexibility and funding to advance our potential best-in-class HIF-2a inhibitor for the treatment of #kidneycancer. Read more about this news https://bit.ly/3T2iyRK
Arcus Biosciences
Biotechnology
Hayward, California 22,464 followers
Global, biopharmaceutical company at the forefront of designing precision combinations in the pursuit of cures
Über uns
Arcus Biosciences is a rapidly growing, clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines that may have the potential to help people with cancer live longer. Located in the San Francisco bay area, Arcus Biosciences offers a competitive compensation and benefits package, including aggressive participation in the growth of the company in the form of stock option grants. Arcus has an ambitious undertaking and expects to become a force in the discovery, development and commercialization of novel combination therapies to treat cancer in areas of high unmet need. Our employees enjoy operating in an exceptionally dynamic and team-driven environment in which the “rule book” has not yet been written.
- Website
-
http://www.arcusbio.com
External link for Arcus Biosciences
- Industrie
- Biotechnology
- Größe des Unternehmens
- 501-1,000 employees
- Hauptsitz
- Hayward, California
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2015
- Spezialitäten
- Protein Therapeutics, Immuno-oncology, Medicinal Chemistry, and Large Molecule Drug Discovery
Standorte
-
Primäre
3928 Point Eden Way
Hayward, California 94545, US
-
1800 Sierra Point Pkwy
Brisbane, California 94005, US
Employees at Arcus Biosciences
-
Emily Walsh
Talent Acquisition & HR Consultant, Pharmaceutical Research, Development & Operations
-
Leslie Mesones Miller
Talent & Leadership Development | Team Effectiveness | Executive Coaching | HR Business Partnership – Understands and leverages individual and team…
-
Eric Matthews
Chief Commercial Officer, Arcus Biosciences
-
Matt Donnelly
Supply Chain and Operations Management Executive | Building and Leading High Performing Organizations
Aktualisierungen
-
For the 7th year, Arcus proudly sponsored and participated in the American Cancer Society East Bay #RelayForLife event, joining thousands of others across the country seeking to end cancer. At this year’s event, Team Arcus fundraised for the Society’s ongoing efforts in research, patient support, and advocacy. We believe in the power of community and science to make a change for those living with cancer – whether via cutting-edge research, or by fostering hope, connections and resilience within our communities.
-
-
This week we presented new research at #ACSFall2024 on the discovery and optimization of casdatifan, our investigational HIF-2a inhibitor. Learn more about our findings being presented in an oral session by Ken Lawson here: https://bit.ly/3WmLBzq
-
-
Digital artist and designer Henry Daubrez watched his parents go through the highs and lows of their own cancer journeys when he was younger, focusing every day on when the cancer would be gone. That day never came for either of his parents and one day, years later, he was faced with his own #kidneycancer diagnosis. One year later, he lives with no signs of cancer and finds peace in helping others share their cancer journeys. View his self-portrait and the entire digital gallery at AIPortraitsOfCancer.com. #PortrAItsofCancer
-
Over the past few weeks, Arcus employees have been keeping up with the #Paris2024 Summer #Olympics from our offices, and recently cheered on Bay Area legend Steph Curry and the rest of Team USA Basketball as they won their semifinal match. Watching incredible athletes compete reminds us of the dedication and teamwork that drives innovation in the work we do here at Arcus. Here’s to teamwork, perseverance and cheering on the best!
-
-
We're reporting our second-quarter financial results and an update on our clinical-stage pipeline. https://bit.ly/4fweS4h
-
-
May, a new young mom, and her family were shocked by her #lungcancer diagnosis. Despite various types of treatment and multiple recurrences, she has never let her diagnosis define her. In the midst of the unknown, she is at peace. May's family and unwavering faith remind her that there is nothing to fear in this world, not even cancer. This #WorldLungCancerDay, view May's portrait and the rest of the digital gallery at AIPortraitsOfCancer.com #PortrAItsofCancer LUNGevity Foundation #WLCD24
-
We had the honor of welcoming Natalie Phelps, a young mother of two and #coloncancer advocate with the Colorectal Cancer Alliance, to speak at Arcus. Natalie spoke to her firsthand account of the extraordinary challenges that people with cancer face every day. She shared insights into how people make treatment decisions such as weighing efficacy with side effects and how the healthcare industry can make it easier for patients and caregivers to navigate finding clinical trials. Her raw, honest and at times heartbreaking journey was both moving and eye-opening, a powerful motivation to continue to think differently and strive for breakthroughs. People like Natalie are waiting. Thank you, Natalie, for sharing your story.
-
-
Last week we presented clinical findings at #KCRS24 on our investigational small molecule HIF-2α inhibitor being developed in #kidneycancer. It’s always inspiring to join such a dedicated community of clinicians, researchers and scientists working together to make a meaningful difference for those living with this disease. Thank you for having us KidneyCAN! Access our poster here: https://bit.ly/3WmLBzq
-
-
This afternoon, our CMO Dimitry Nuyten will be presenting at KidneyCAN’s #KCRS24 Biotech Showcase where he’ll provide an overview of Arcus’s research in #kidneycancer, including our small molecule HIF-2α inhibitor. We look forward to an opportunity to discuss emerging therapeutics being developed for kidney cancer and collaborate with fellow clinical and translational researchers driving these advancements. Learn more about our science here: https://bit.ly/3S6i0tA
-
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
Letzte Runde
Eigenkapital nach dem IPOUS$ 320.0M
Investoren